Video Experimental Relacionado
Updated: Jul 17, 2026
06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
El nuevo precursor de la enfermedad de Alzheimer, la proteína amiloide, muestra actividad inhibidora de la proteasa
N Kitaguchi1, Y Takahashi, Y Tokushima
1Life Science Research Laboratories, Asahi Chemical Industry Co. Ltd., Shizuoka, Japan.
Nature
|February 11, 1988
Resumen
Los investigadores identificaron una nueva forma de proteína precursora de amiloide (APP) con actividad inhibidora de la proteasa. Este descubrimiento puede arrojar luz sobre el procesamiento anormal de la APP en la enfermedad de Alzheimer.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Biología Molecular Biología Molecular
- Genética La genética.
Sus antecedentes:
- La enfermedad de Alzheimer implica depósitos de beta-proteína amiloide (Aβ) en el cerebro.
- El ADN complementario (ADNc) que codifica la proteína precursora de amiloide (APP) ha sido clonado previamente a partir de tejido cerebral humano.
Objetivo del estudio:
- Investigar nuevas formas de APP y sus posibles funciones.
- Explorar las implicaciones del empalme alternativo en la expresión génica de la APP.
Principales métodos:
- Aislamiento de ADNc de una línea celular de glioblastoma humano.
- Secuenciación de ADNc aislado y ADN genómico.
- Transfección de células COS-1 con APP cDNA y evaluación de la inhibición de la tripsina.
- Análisis de las especies de ARN mensajero (ARNm) en el cerebro humano.
Principales resultados:
- Se identificó un nuevo ADNc que contiene un inserto de 225-nucleótido, que difiere del ADNc de la APP previamente reportado.
- La secuencia de aminoácidos deducida del insert mostró homología con la familia básica de inhibidores de la tripsina.
- Las células transfectadas que expresan el ADNc APP más largo exhibieron una mayor inhibición de la tripsina.
- El empalme alternativo del gen APP da como resultado al menos tres especies distintas de ARNm en el cerebro humano.
Conclusiones:
- Las variantes APP más largas poseen actividad inhibidora de la proteasa.
- Esta inhibición de la proteasa puede estar relacionada con el catabolismo aberrante de la APP, lo que potencialmente contribuye a la patología de la enfermedad de Alzheimer.
Videos de Conceptos Relacionados
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...